Evolent Health Inc (EVH)
Official siteHEALTHCARE • HEALTH INFORMATION SERVICES • NYSE
Market Cap: $554.22M
Last updated: Nov 17, 2026 at 11:05 AM ET
Evolent Health Inc (EVH) Earnings: Report Dates and Results
Evolent Health (EVH) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, Evolent Health reported EPS of -$0.04, above the -$0.05 estimate. It beat the EPS estimate in 2 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
EVH has an expected report date of Feb 22, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 100.0% above the $0.08 reported for the quarter ended Dec 31, 2025.
EVH Earnings Call
The latest EVH earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 39 quarters below that had an estimate, EVH beat 22, missed 13 and matched 4. Revenue for the quarter ended Sep 30, 2026 was $725.37M, up 51.3% from $479.53M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.04 | -$0.05 | N/A | +20.00% | Beat | -180.0% | 9 | 5 up, 3 down | Nov 5, 2026 | $725.37M |
| Jun 30, 2026 | -$0.11 | -$0.10 | N/A | -10.00% | Miss | N/A | 10 | 0 up, 1 down | Aug 6, 2026 | $652.52M |
| Mar 31, 2026 | -$0.02 | $0.05 | N/A | -136.83% | Miss | -133.3% | 10 | 0 up, 4 down | May 7, 2026 | $496.25M |
| Dec 31, 2025 | $0.08 | $0.05 | -$0.05 - $0.09 | +60.00% | Beat | N/A | 12 | 0 up, 1 down | Feb 24, 2026 | $468.72M |
| Sep 30, 2025 | $0.05 | $0.10 | $0.05 - $0.20 | -50.00% | Miss | +25.0% | 11 | 0 up, 3 down | Nov 6, 2025 | $479.53M |
| Jun 30, 2025 | -$0.17 | $0.08 | $0.05 - $0.15 | -312.50% | Miss | -156.7% | 10 | 0 up, 0 down | Aug 7, 2025 | $444.33M |
| Mar 31, 2025 | $0.06 | $0.10 | $0.03 - $0.15 | -40.00% | Miss | -82.4% | 9 | 0 up, 7 down | May 8, 2025 | $483.65M |
| Dec 31, 2024 | -$0.02 | $0.01 | -$0.13 - $0.09 | -260.00% | Miss | -108.7% | 12 | 1 up, 9 down | Feb 20, 2025 | $646.54M |
| Sep 30, 2024 | $0.04 | $0.34 | $0.22 - $0.41 | -88.24% | Miss | -86.7% | 12 | 0 up, 1 down | Nov 7, 2024 | $621.40M |
| Jun 30, 2024 | $0.30 | $0.25 | $0.15 - $0.32 | +20.00% | Beat | +114.3% | 11 | 0 up, 1 down | Aug 8, 2024 | $647.14M |
| Mar 31, 2024 | $0.34 | $0.30 | $0.10 - $0.34 | +13.33% | Beat | +61.9% | 11 | 2 up, 0 down | May 9, 2024 | $639.65M |
| Dec 31, 2023 | $0.23 | $0.15 | $0.01 - $0.30 | +53.33% | Beat | +130.0% | 9 | 0 up, 0 down | Feb 22, 2024 | $556.05M |
| Sep 30, 2023 | $0.30 | $0.10 | -$0.14 - $0.16 | +200.00% | Beat | -49.2% | 7 | 0 up, 0 down | Nov 2, 2023 | $511.01M |
| Jun 30, 2023 | $0.14 | $0.15 | -$0.08 - $0.19 | -6.67% | Miss | +40.0% | 7 | 0 up, 0 down | Aug 2, 2023 | $469.14M |
| Mar 31, 2023 | $0.21 | $0.19 | $0.09 - $0.39 | +10.53% | Beat | +75.0% | 8 | 1 up, 0 down | May 3, 2023 | $427.69M |
| Dec 31, 2022 | $0.10 | $0.16 | $0.05 - $0.56 | -37.50% | Miss | +25.0% | 7 | 1 up, 0 down | Feb 22, 2023 | $382.43M |
| Sep 30, 2022 | $0.59 | $0.10 | $0.06 - $0.24 | +490.00% | Beat | N/A | 7 | 0 up, 0 down | Nov 2, 2022 | $352.58M |
| Jun 30, 2022 | $0.10 | $0.05 | -$0.01 - $0.09 | +100.00% | Beat | N/A | 7 | 0 up, 0 down | Aug 2, 2022 | $319.94M |
| Mar 31, 2022 | $0.12 | $0.00 | -$0.11 - $0.05 | N/A | N/A | N/A | 5 | 1 up, 0 down | May 4, 2022 | $297.06M |
| Dec 31, 2021 | $0.08 | $0.01 | -$0.08 - $0.09 | +700.00% | Beat | N/A | 6 | 1 up, 0 down | Feb 23, 2022 | $248.36M |
| Sep 30, 2021 | -$0.03 | -$0.03 | -$0.12 - $0.03 | 0.00% | In line | N/A | 7 | N/A | Nov 3, 2021 | $222.47M |
| Jun 30, 2021 | -$0.02 | -$0.03 | -$0.12 - $0.02 | +33.33% | Beat | N/A | 5 | N/A | Aug 4, 2021 | $222.06M |
| Mar 31, 2021 | -$0.01 | -$0.07 | -$0.15 - $0.03 | +85.71% | Beat | N/A | 8 | N/A | May 5, 2021 | $215.07M |
| Dec 31, 2020 | -$0.01 | -$0.05 | -$0.09 - -$0.01 | +80.00% | Beat | N/A | 8 | N/A | Feb 25, 2021 | $246.54M |
| Sep 30, 2020 | -$0.03 | -$0.05 | -$0.11 - $0.02 | +40.00% | Beat | N/A | 10 | N/A | Nov 5, 2020 | $239.57M |
| Jun 30, 2020 | -$0.03 | -$0.10 | -$0.19 - -$0.03 | +70.00% | Beat | N/A | 11 | N/A | Aug 4, 2020 | $217.30M |
| Mar 31, 2020 | -$0.14 | -$0.13 | -$0.22 - -$0.10 | -7.69% | Miss | N/A | 9 | N/A | May 7, 2020 | $221.23M |
| Dec 31, 2019 | -$0.07 | -$0.04 | -$0.08 - $0.01 | -75.00% | Miss | N/A | 10 | N/A | Feb 25, 2020 | N/A |
| Sep 30, 2019 | -$0.09 | -$0.12 | -$0.23 - -$0.05 | +25.00% | Beat | N/A | 12 | N/A | Nov 5, 2019 | $220.14M |
| Jun 30, 2019 | -$0.26 | -$0.23 | -$0.34 - -$0.12 | -13.04% | Miss | N/A | 13 | N/A | Aug 6, 2019 | $383.92M |
| Mar 31, 2019 | -$0.31 | -$0.33 | -$0.57 - -$0.18 | +6.06% | Beat | -1650.0% | 14 | N/A | May 7, 2019 | $197.76M |
| Dec 31, 2018 | -$0.07 | -$0.04 | -$0.08 - $0.01 | -75.00% | Miss | N/A | 14 | N/A | Feb 26, 2019 | $193.10M |
| Sep 30, 2018 | -$0.04 | -$0.04 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 6, 2018 | $149.95M |
| Jun 30, 2018 | -$0.03 | -$0.04 | -$0.07 - -$0.01 | +25.00% | Beat | N/A | 15 | N/A | Aug 7, 2018 | $144.30M |
| Mar 31, 2018 | $0.02 | -$0.04 | -$0.07 - -$0.02 | +150.00% | Beat | N/A | 12 | N/A | May 9, 2018 | $139.71M |
| Dec 31, 2017 | -$0.04 | -$0.04 | -$0.07 - -$0.02 | 0.00% | In line | N/A | 14 | N/A | Feb 27, 2018 | $113.73M |
| Sep 30, 2017 | -$0.04 | -$0.08 | -$0.12 - -$0.07 | +50.00% | Beat | N/A | 13 | N/A | Nov 2, 2017 | $107.91M |
| Jun 30, 2017 | -$0.13 | -$0.13 | -$0.16 - -$0.10 | 0.00% | In line | N/A | 11 | N/A | Aug 7, 2017 | $107.07M |
| Mar 31, 2017 | -$0.14 | -$0.16 | N/A | +12.50% | Beat | N/A | N/A | N/A | May 9, 2017 | $106.24M |
| Dec 31, 2016 | -$0.18 | -$0.20 | N/A | +10.00% | Beat | N/A | N/A | N/A | Feb 28, 2017 | $88.01M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.02, down 97.0% from the year before. It was -$0.57 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.02 | -97.0% |
| Dec 31, 2024 | $0.66 | -25.0% |
| Dec 31, 2023 | $0.88 | N/A |
| Dec 31, 2022 | $0.91 | +4450.0% |
| Dec 31, 2021 | $0.02 | N/A |
| Dec 31, 2020 | -$0.21 | N/A |
| Dec 31, 2019 | -$0.73 | N/A |
| Dec 31, 2018 | -$0.12 | N/A |
| Dec 31, 2017 | -$0.35 | N/A |
| Dec 31, 2016 | -$0.57 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,100 words across 12 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 6,071 | 12 | |
| 2026Q2 | Jun 30, 2026 | 6,533 | 14 | |
| 2026Q1 | Mar 31, 2026 | 5,387 | 12 | |
| 2025Q4 | Dec 31, 2025 | 8,929 | 17 | |
| 2025Q3 | Sep 30, 2025 | 5,778 | 13 | |
| 2025Q2 | Jun 30, 2025 | 5,236 | 11 | |
| 2025Q1 | Mar 31, 2025 | 6,406 | 14 | |
| 2024Q4 | Dec 31, 2024 | 7,969 | 16 |
2026Q3 Earnings Call
Opening remarks
Seth Blackley CEO Good morning, and thank you for joining us. Today, we reported third quarter results that we believe reflect strong continued progress against the priorities we laid out at the beginning of the year. We grew our Performance Suite business, improved our care margins, and stayed disciplined on operating expenses, all while continuing to innovate at the core of our business. For the quarter, Evolent reported total revenue of $725 million, up 11% versus Q2, and Adjusted EBITDA of $34 million, up approximately 22% sequentially. Our medical expense ratio, or MER, was 93%, compared with 95% in the second quarter. The improvement reflects favorable in-year claims development and contractual adjustments. Mario will provide more details on those drivers in a few moments. Based on our results through the first nine months and our current view of the fourth quarter, we are reiterating our full-year revenue guidance of $2.6 billion-$2.7 billion and raising our Adjusted EBITDA guidance to $130 million-$135 million. Before turning it over to Mario, I want to talk you through four topics. One, the strength of our customer relationships and the related growth. Two, updates from our 2026 Performance Suite launches. Three, how we are both broadening our product footprint and accelerating our AI innovation. And fourth, our balance sheet. Let's start with the initial topic of customer relationships and growth. As we've discussed on previous calls, renewals and expansions are at the heart of our growth story. I'd like to share several proof points of that today. First, we renewed our largest Surgical Management customer contract for an additional four years. You will recall, Surgical Management is the IPG business we acquired in 2022. We view this as more than a renewal. It's a longstanding partner committing to a multi-year deal, demonstrating that our model works and that they want us at their side managing musculoskeletal and cardiovascular care for the long run. Second, an existing client signed an agreement to expand their oncology offering, covering several additional states and approximately 1 million commercial lives, with go-live expected January 1, 2027. This is our first expansion with this client, and we believe it demonstrates the trust they've placed in us, but also something more strategically important. It's significant to note that this expansion will also include Member Navigation across all existing and new lives, meaning we're not just growing with the client, we're broadening the footprint by adding our member-facing solution. This is exactly the kind of product breadth expansion that defines our next phase of growth, taking a client under contract with one solution and giving them a reason to trust us with additional solutions.
Frequently Asked Questions About EVH
When is Evolent Health's next earnings date?
Evolent Health's next earnings report is expected for Feb 22, 2027.
Did EVH beat earnings estimates last quarter?
Yes. Evolent Health reported EPS of -$0.04 for the quarter ended Sep 30, 2026, above the -$0.05 estimate, a 20.00% surprise.
What EPS do analysts expect from EVH next quarter?
The consensus EPS estimate for Evolent Health for the quarter ending Dec 31, 2026 is $0.16 from 16 analysts, with estimates from $0.07 to $0.22.
How often does EVH beat earnings estimates?
Evolent Health beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -91.17%.
EVH pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors